How to Inject Milavatide Injections to Ensure Best Results

Mifamurtide injection (Mifamurtide) has significant efficacy as an adjuvant therapy in the treatment of patients with high-grade, resectable, non-metastatic osteosarcoma. However, in order to ensure its therapeutic effect, the injection must be carried out strictly in accordance with the recommended usage and dosage. The administration method of mivamutide is usually intravenous injection, and each injection process lasts about 1 hour to ensure the effective absorption and effect of the drug in the body.

The recommended dose of mivamutide is2 mg/㎡ body surface area, administered by intravenous injection. In order to ensure that the drug can fully exert its immune-enhancing effect, the injection process needs to be maintained for a certain period of time. Each administration lasts about 1 hour, and the injection speed must be slow to avoid adverse reactions or side effects that may be caused by too fast injection. Since mivamutide is an immunomodulator and its effect relies on the drug entering the body through the blood circulation and exerting its effect through the immune system, the slowness of the injection is crucial to the effect of the drug.

The frequency of dosing of mivamutide is also very important. The recommended treatment regimen is two injections per week for 12 weeks after surgery, with an interval of at least 3 days between each injection. Treatment at this stage aims to eliminate any cancer cells that may remain after surgery by strengthening the immune response. Subsequently, the maintenance treatment phase was entered, with injections once a week for 24 weeks, with a total treatment course of 36 weeks and a total of 48 injections. Through such a treatment plan, the patient's immune system can be continuously activated at different stages, thereby producing a lasting inhibitory effect on tumor cells.

During the injection process, the above dosage and administration time must be strictly adhered to to ensure the therapeutic effect. Any deviation in administration, especially injection too fast or inaccurate dosage, may affect the immune-enhancing effect of mivamutide and may even lead to side effects or treatment failure. Therefore, when patients receive mivamutide treatment, they must be under the guidance of professional medical staff to ensure that the drug enters the body correctly and effectively.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/mepact